Frontlight ResearchEarly access
Taking people in NetherlandsPhase 1/2
Two skin creams added to standard treatment for advanced melanoma
Tests Monobenzon and Imiquimod creams alongside usual care in adults with advanced melanoma.
Key facts
- Who runs it
- Amsterdam UMC Stichting
- Where
- Amsterdam, NetherlandsSee the site
- Trial code
- Registry title
- Research on two creams (Monobenzon / Imiquimod) together with the standard treatment for advanced or metastatic melanoma (ImMI).
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 18 people, planned
- Started
- 18 Sept 2026
- Expected to end
- 1 Mar 2028
- Type of study
- Interventional
- Record updated
- 13 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or metastatic melanoma who will get two creams (Monobenzon and Imiquimod) together with the standard treatment.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Advanced or metastatic melanoma
Where in Netherlands
- Amsterdam UMC StichtingAmsterdam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Two skin creams added to standard treatment for advanced melanomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 13 April 2026